Please Wait...

Grünenthal Selects BioClinica OnPoint Clinical Trial Management System

– Leading Pain Management Company Standardizes on BioClinica CTMS Technology –

March 5, 2012

March 5, 2012.  NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Grünenthal GmbH has signed a global license agreement for BioClinica OnPoint CTMS to support its ongoing clinical trials. BioClinica OnPoint CTMS helps clinical trial sponsors to easily consolidate their data, share this data and improve trial management by using Microsoft SharePoint 2010 and Microsoft Office 2010.

Grünenthal selected BioClinica OnPoint after a thorough evaluation of the leading enterprise-scale CTMS solutions. The assessment team was comprised of Grünenthal experts from various functional areas. The workshops demonstrated that the requirements specified by Grünenthal could be delivered faster and most cost-effectively using OnPoint. Grünenthal was particularly impressed with BioClinica's ability to integrate with other clinical systems, the extensibility of this consolidated data via SharePoint-based dashboards and the fact that OnPoint allows clinical staff to do much of their work within the familiar environment of Microsoft Office applications.

"After careful review of the commercially available CTMS solutions, we felt that BioClinica's platform provides our clinical staff with a timely and comprehensive overview of relevant data and thus helps to make planning more efficient," said Hazel Collie, Head of Quality & Systems at Grünenthal. "In this regard, OnPoint supports our objective to enhance our innovation process, allowing us to develop solutions to improve the quality of life of our patients."

"Life sciences companies of all sizes face increased pressure to efficiently manage clinical trials while bringing drugs to market quickly," said Andrea McGonigle, managing director, Life Sciences, Microsoft Corp. "BioClinica uses Microsoft SharePoint and Office to help clients gain a comprehensive, real-time view into trial performance and act on that information."

Mark Weinstein, CEO of BioClinica, said, "We are proud to be selected to support Grünenthal's clinical trial support needs, world-wide. This agreement demonstrates the results of our continuing commitment to deliver innovative technology solutions that help customers execute and manage their clinical trials with greater efficiency and speed."

About the Grünenthal Group
The Grünenthal Group is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company and to be a leader in therapy innovation. Altogether, the Grünenthal Group has affiliates in 30 countries worldwide. Grünenthal products are sold in more than 150 countries and approx. 4,500 employees are working for the Grünenthal Group globally. In 2010, Grünenthal reached revenues of about 910M €. For more information: www.grunenthal.com.

About Bioclinica
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging & Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Randomization & Trial Supply Management; Financial Lifecycle Solutions; Safety & Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of investigative sites, patient recruitment services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices and research sites in the U.S., Europe, Asia, and Latin America.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @Xtalks: Outsourcing to #CROs? Top 5 Reasons to Consider Bringing CTMS & Quality Management/RBM Systems in House @bioclinica https://t.c…
bioclinica (9 hours ago)
Webinar tom! Take a fresh look at in-house vs. outsourced #CTMS & #RBM systms via case studies & ROI… https://t.co/cXKG3UgaGp
bioclinica (14 hours ago)
Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned. Join us at 11 AM EDT today in a live webinar.… https://t.co/1jiraT9cSL
bioclinica (Yesterday)
Still time to join us for tomorrow's webinar: Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned https://t.co/Ho13oUxdly
bioclinica (2 days ago)
ICYMI: Clean Patient Optics: helping #ClinicalResearch teams meet or beat database lock. News https://t.co/adWwISw4Cu
bioclinica (2 days ago)
Vaccine clinical trials: Boost senior participation following simple advice from Dr. Craig Curtis… https://t.co/rYg9u25vMf
bioclinica (5 days ago)

Latest Blogs: